Evidence map›Paper›PMID 42453405›Full record

ArticleActa pharmaceutica Sinica. B2026

Photobiomodulation-reprogrammed extracellular vesicles delivered

Yining Liu, Sijia Li, Ao Cai, Wei Li, Wanyu Zhang, Tianlong Li, Manjie Zhang, Chenlu Liu, Wenya Ma, Yuqing Lin and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yining LiuDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Sijia LiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Ao CaiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Wei LiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Wanyu ZhangDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Tianlong LiSchool of Mechanical and Electrical Engineering, Harbin Institute of Technology, Harbin 150006, China.
Manjie ZhangDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Chenlu LiuSchool of Mechanical and Electrical Engineering, Harbin Institute of Technology, Harbin 150006, China.
Wenya MaDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Yuqing LinDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Hanjing LiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Xinlu GaoDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Zhongyu RenDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Hang YuDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Haoyu JiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Xiuxiu WangDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Yang YuDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
Xu LiuDepartment of Laboratory Medicine at the Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
Yifu ShenDepartment of Laboratory Medicine at the Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
Ye TianDepartment of Pathophysiology, Key Laboratory of Cardiovascular Physiology, Harbin Medical University, Harbin 150081, China.
Faqian LiDepartment of Pathology & Laboratory Medicine, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Yu LiuDepartment of Laboratory Medicine at the Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, China.
Zhenwei PanState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (The State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.
Baofeng YangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (The State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin 150081, China.
Benzhi CaiDepartment of Pharmacy at the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell-derived extracellular vehicles (EVs) hold great therapeutic potential for myocardial infarction (MI). However, the efficient production of EVs with high bioactivity remains a critical bottleneck limiting their clinical translation. Here, we demonstrate that conditioned photobiomodulation (PBM) with green light is capable of activating human embryonic stem cells (hESCs) to secrete more EVs with superior cardioprotective activity. These PBM-reprogrammed hESC-EVs improve cardiac recovery in a murine MI model by promoting cardiomyocyte proliferation and angiogenesis while inhibiting apoptosis. Notably, we validate that these EVs similarly enhance the survival and proliferation of human cardiomyocytes, underscoring their translational potential. Further analysis reveals that this benefit is due to the higher miR-423-3p content in reprogrammed hESC-EVs, which enhances glycolytic metabolism and restores mitochondrial function by regulating the ZBTB7A/PKM2 axis. Moreover, we synthesize a methacryloyl hydrogel microneedle patch with superior biocompatibility, biodegradability, and mechanical strength for loading hESC-EVs, and convey the patch to the infarcted heart

Indexed as

Cardiac repairExtracellular vesicleGlycolysis metabolismMicroneedle patchMicroRNAMyocardial infarctionPhotobiomodulationStem cell

Identifiers

PMID42453405
PMCPMC13366298

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.